Credit Suisse Reinstates Coverage on Amylin Pharmaceuticals (AMLN) at Outperform
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Price: $30.98 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 19
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 19
Join SI Premium – FREE
Credit Suisse reinstates coverage on Amylin Pharmaceuticals (NASDAQ: AMLN) with an Outperform. PT raised from $14 to $22.
For an analyst ratings summary and ratings history on Amylin Pharmaceuticals click here. For more ratings news on Amylin Pharmaceuticals click here.
Shares of Amylin Pharmaceuticals closed at $17.61 yesterday.
For an analyst ratings summary and ratings history on Amylin Pharmaceuticals click here. For more ratings news on Amylin Pharmaceuticals click here.
Shares of Amylin Pharmaceuticals closed at $17.61 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ADC Therapeutics (ADCT) PT Lowered to $5 at Guggenheim
- Wedbush Starts Immunic Inc. (IMUX) at Outperform
- Gemini Space Station (GEMI) PT Lowered to $6 at Needham
Create E-mail Alert Related Categories
Analyst PT Change, New CoverageRelated Entities
Credit SuisseSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
